Last reviewed · How we verify
Adapalene Gel, 0.1%
Adapalene is a third-generation retinoid that binds to retinoic acid receptors (RARs) to normalize skin cell differentiation and reduce inflammation in acne.
Adapalene is a third-generation retinoid that binds to retinoic acid receptors (RARs) to normalize skin cell differentiation and reduce inflammation in acne. Used for Acne vulgaris, Photoaging and fine wrinkles (off-label use).
At a glance
| Generic name | Adapalene Gel, 0.1% |
|---|---|
| Also known as | Differin® Gel, 0.1% |
| Sponsor | Galderma R&D |
| Drug class | Retinoid (third-generation) |
| Target | Retinoic acid receptors (RARα, RARβ, RARγ) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Adapalene selectively activates retinoic acid receptor gamma (RARγ) and other RAR subtypes, promoting keratinocyte differentiation and reducing comedone formation. It also exhibits anti-inflammatory properties by modulating cytokine production and reducing sebum production, making it effective for treating acne vulgaris. Unlike first-generation retinoids, adapalene has improved tolerability and a lower potential for irritation.
Approved indications
- Acne vulgaris
- Photoaging and fine wrinkles (off-label use)
Common side effects
- Erythema
- Scaling and dryness
- Pruritus
- Photosensitivity
- Burning sensation
Key clinical trials
- Topical 5% Spironolactone Gel Versus 0.1% Adapalene Gel for Acne Vulgaris: A Randomized Split-Face Study (PHASE2)
- Auricular Acupressure Combined With Adapalene for the Treatment of Acne Vulgaris (NA)
- Experience With Topical Acne Treatment (EARLY_PHASE1)
- Efficacy and Safety of Adapalene Gel and Hyaluronic Acid Versus Adapalene Gel Alone in Mild to Moderate Acne Vulgaris (PHASE4)
- Comparison of Effectiveness of Topical Retinoids Versus Liquid Nitrogen in Treatment of Plantar Warts(Viral Infection) (PHASE4)
- Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris (PHASE3)
- MC RCT - BPO vs Adapalene (PHASE3)
- Long-term Study of Efficacy/Safety of Adapalene/Benzoyl Peroxide Topical Gel in Acne Vulgaris Subjects (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adapalene Gel, 0.1% CI brief — competitive landscape report
- Adapalene Gel, 0.1% updates RSS · CI watch RSS
- Galderma R&D portfolio CI